TY  - JOUR
AU  - Bellido, Virginia
AU  - Abreu-Padin, Cristina
AU  - Catarig, Andrei-Mircea
AU  - Clark, Alice
AU  - Barreto-Pittol, Sofia
AU  - Delgado, Elias
PY  - 2022
DO  - 10.3390/jcm11174938
SN  - 2077-0383
UR  - http://hdl.handle.net/10668/21336
T2  - Journal of clinical medicine
AB  - Type 2 diabetes (T2D) is a complex disease for which an individualised treatment approach is recommended. Once-weekly (OW) semaglutide is a glucagon-like peptide-1 receptor agonist approved for the treatment of insufficiently controlled T2D. The aim...
LA  - en
PB  - MDPI AG
KW  - HbA1c
KW  - SURE study
KW  - body weight
KW  - glucagon-like peptide-1 receptor agonist
KW  - real-world evidence
KW  - semaglutide
KW  - type 2 diabetes
KW  - Diabetes Mellitus, Type 2
KW  - Semaglutide
KW  - Glucagon‑Like Peptide‑1 Receptor Agonists
KW  - Glycated Hemoglobin / analysis
KW  - Body Weight
KW  - Cohort Studies
TI  - Once-Weekly Semaglutide Use in Patients with Type 2 Diabetes: Results from the SURE Spain Multicentre, Prospective, Observational Study.
TY  - research article
VL  - 11
ER  -